Summit Trail Advisors LLC Buys 322 Shares of Danaher Co. (NYSE:DHR)

Summit Trail Advisors LLC grew its stake in Danaher Co. (NYSE:DHR) by 3.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,871 shares of the conglomerate’s stock after purchasing an additional 322 shares during the quarter. Summit Trail Advisors LLC’s holdings in Danaher were worth $2,719,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Tsfg LLC boosted its stake in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares in the last quarter. nVerses Capital LLC bought a new position in shares of Danaher in the second quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the second quarter valued at approximately $25,000. Cape Investment Advisory Inc. bought a new stake in shares of Danaher during the fourth quarter valued at approximately $25,000. Finally, Redmont Wealth Advisors LLC purchased a new position in Danaher in the 1st quarter worth approximately $30,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

NYSE:DHR opened at $272.63 on Friday. The company has a market capitalization of $201.93 billion, a P/E ratio of 46.21, a P/E/G ratio of 4.48 and a beta of 0.83. The business’s 50-day moving average is $267.62 and its 200 day moving average is $257.14. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the company earned $2.05 EPS. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. On average, equities research analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Evercore ISI decreased their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Royal Bank of Canada restated an “outperform” rating and set a $300.00 target price on shares of Danaher in a research report on Friday, September 6th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Robert W. Baird lifted their price target on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, Bank of America upped their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $278.94.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Linda Filler sold 3,928 shares of Danaher stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the completion of the sale, the director now directly owns 41,149 shares in the company, valued at $11,501,145.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 over the last ninety days. Company insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.